Obesity

Intranasal Oxytocin for Obesity

NEJM EvidPublished Randomised controlled trial

Authors' conclusion

In this randomized, placebo-controlled trial in adults with obesity, intranasal oxytocin administered four times daily for 8 weeks did not reduce body weight.

Study context

Population
Adults with obesity; 54% women, mean age 33.6 ± 6.2 years, BMI 36.9 ± 4.9randomized 1:1
Participants
61 adults
Comparison
Intranasal oxytocin vs placebo
Primary endpoint
Change in body weight (kg) from baseline
Follow-up
Week 8
Methodological detailsdouble-blind, placebo-controlled, stratified by sex and obesity class
  • Double-blind
  • Placebo-controlled
  • Stratified by sex and obesity class

Primary result

As reported in the abstract

Body weight change · baseline to week 8

Oxytocin

0.20

kg

Placebo

0.26

kg

P = 0.934

Secondary outcomes

OutcomeDifference (g) (95% CI)
Total fat mass change · baseline to week 8196.0 (−1036 to 1428)
OutcomeDifference (cm²) (95% CI)
Visceral fat change · baseline to week 83.1 (−11.0 to 17.2)
OutcomeDifference (95% CI)
Liver fat fraction change · baseline to week 8−0.01 (−0.03 to 0.01)
OutcomeDifference (kcal/day) (95% CI)
Resting energy expenditure change (adjusted for lean mass) · baseline to week 8−64.0 (−129.3 to 1.4)

Kcal

OutcomeOxytocinPlaceboDifference (kcal) (95% CI)
Caloric intake at test meal change · baseline to week 6−31.4120.6−152.0 (−302.3 to −1.7)

Safety

Serious adverse events
0
Incidence and severity of adverse events did not differ between groups

Original publication

Intranasal Oxytocin for Obesity. NEJM Evid. Published 23 April 2024. doi:10.1056/evidoa2300349

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.